Product switching in the pharmaceutical industry: Ripe for antitrust scrutiny

Journal of Generic Medicines

Volumn 7, Issue 2, 2010, Pages 119-130

  Silber, Seth ^a   Kuritz, Kara ^a  

^a C/o Wilson Sonsini Goodrich and Rosati ^*  (United States)

Author keywords

Antitrust; Hatch Waxman; Pharmaceutical; Product hopping; Product switching; Sherman act

Indexed keywords

ESOMEPRAZOLE; FENOFIBRATE; GENERIC DRUG; NON PRESCRIPTION DRUG; OMEPRAZOLE;

BIOEQUIVALENCE; BIOTECHNOLOGY; COUNSELING; DRUG COST; DRUG DOSAGE FORM; DRUG EFFICACY; DRUG FORMULATION; DRUG INDUSTRY; DRUG LEGISLATION; DRUG MANUFACTURE; DRUG SAFETY; ECONOMIC ASPECT; FOOD AND DRUG ADMINISTRATION; HEALTH CARE QUALITY; HEARTBURN; PATENT; PRESCRIPTION; PURCHASING; REVIEW; STRATEGIC PLANNING;

EID: 77951857913     PISSN: 17411343     EISSN: 17417090     Source Type: Journal    
DOI: 10.1057/jgm.2010.1     Document Type: Review

References (29)

1. FTC, Statement on Protecting Consumer Access to Generic Drugs: The Benefi ts of a Legislative Solution to Anticompetitive Patent Settlements in the Pharmaceutical Industry before the Subcommittee on Commerce, Trade, and Consumer Protection, US H. R. (2 May 2007).
2. Obama/Biden Campaign Website, Seniors & Social Security, http://www.barackobama.com/issues/seniors/(last visited 19 February 2009).
3. 21 U. S. C. § § 301 et seq.
4. 21 U. S. C. § 355 (a).
5. 21 U. S. C. § 355 (j).
6. 21 U. S. C. § 355 (j) (2) (A).
7. 21 U. S. C. § 355 (j) (2) (A) (viii).
8. 21 U. S. C. § 355 (j) (5) (B) (iii).
9. Amoresano, GV. (2007) Branded drug reformulation: The next brand vs generic antitrust battleground. Food & Drug Law Journal 62 (1) : 249-250.
10. US v. Grinnell Corp., 384 US 563 (1966).
11. Spectrum Sports v. McQuillan, 506 US 447 (1993).
12. Abbott Laboratories v. Teva Pharmaceuticals USA, Inc., 432 F. Supp. 2d 408 (D. Del. 2006).
13. The lawsuits triggered the 30-month Hatch-Waxman stay of FDA approval of the generic formulations. In March of 2002, the Northern District of Illinois granted summary judgment to Teva, and the Federal Circuit affi rmed, and in 2003, the district court granted to summary judgment to Impax as well.
14. Berkey Photo, Inc. v. Eastman Kodak Co., 603 F.2d 263 (2d Cir. 1979).
15. US v. Microsoft, 253 F.3d 34 (D. C. Cir. 2001).
16. US v. Dentsply Int ' l, Inc., 399 F.3d 181 (3d Cir. 2005).
17. Howard, S. (2008) Abbott settles tricor class action for $184M. (20 November 2008) Competition Law 360. http://competition. law360.com/print- article/77718.
18. Henson, S. (2010) Abbott Coughs up $23M to Settle Patent Fraud Claims (7 January 2010). Competition Law 360, http://competition. law360.com/print-article/142256.
19. Walgreen Co. v. AstraZeneca Pharms., 534 F. Supp. 2d 146 (D. D. C. 2008).
20. Verizon Commc ' ns v. Law Offi ces of Curtis V. Trinko, 540 US 398 (2004).
21. Aspen Skiing Co. v. Aspen Highlands Skiing Corp., 472 US 585 (1985).
22. Cheng, J. (2008) An antitrust analysis of product hopping in the pharmaceutical industry. Columbia Law Review 108 (6) : 1507-1510.
23. This case has subsequently been transferred to the North District of Georgia, where Defendants ' motion to dismiss is pending.
24. Complaint, FTC v. Watson Pharms., No. CV 09-00598 (C. D. Cal. 27 January 2009), http://www.ftc.gov/os/caselist/0710060/090202androgelcmpt.pdf.
25. Complaint, FTC v. Cephalon, Inc., No. 08-cv-2141-RBS (D. D. C. 13 February 2008), http://www.ftc.gov/os/caselist/0610182/080213complaint.pdf.
26. Complaint, FTC v. Warner Chilcott Holdings Co. III, No. 1:05-cv-02179-CKK (D. D. C. 7 November 2005), http://www.ftc.gov/os/caselist/0410034/ 051107comp0410034%20.pdf.
27. Final Order and Stipulated Permanent Injunction, FTC v. Warner Chilcott Holdings III, No. 1:05-cv-02179-CKK (D. D. C. 23 October 2006), http://www.ftc.gov/os/caselist/0410034/finalorder.pdf.
28. Majoras, D. (2007) Keynote address at the ABA antitrust section fall forum. (15 November 2007), http://www.ftc.gov/speeches/majoras/071115fall.pdf.
29. Leibowitz, J. (2008) Tales from the crypt episodes ' 08 and ' 09: The return of section 5 (Unfair methods of competition in commerce are hereby declared unlawful), FTC section 5 workshop. (17 October 2008), http://www.ftc.gov/speeches/leibowitz/081017section5.pdf.